Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan

被引:172
|
作者
Miyakawa, Shuichi [1 ]
Ishihara, Shin [1 ]
Horiguchi, Akihiko [1 ]
Takada, Tadahiro [2 ]
Miyazaki, Masaru [3 ]
Nagakawa, Takukazu [4 ]
机构
[1] Fujita Hlth Univ, Dept Biliary & Pancreat Surg, Toyoake, Aichi 4701192, Japan
[2] Teikyo Univ, Dept Surg, Tokyo 173, Japan
[3] Grad Sch Med, Dept Gen Surg, Chiba, Japan
[4] Fukuno Hosp, Nanto, Toyama, Japan
来源
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY | 2009年 / 16卷 / 01期
关键词
Biliary tract cancer; Statistics registry; 5-year survival; Stage of disease; Lymph node metastasis; LONG-TERM SURVIVAL; AMPULLARY CARCINOMAS; GALLBLADDER CANCER; SURGERY; CHOLANGIOCARCINOMA; GUIDELINES; MANAGEMENT; RECURRENCE; VATER; EXPERIENCE;
D O I
10.1007/s00534-008-0015-0
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
The results from the Japanese Biliary Tract Cancer Statistics Registry from 1988 to 1998 were reported in 2002. In the present study, we report here selectively summarized data as an overview of the 2006 follow-up survey of the registered cases from 1998 to 2004 for information bearing on problems with the treatment of cancer of the biliary tract. A total of 5,584 patients were registered from 1998 to 2004. The site of cancer was the bile duct in 2,732 patients, the gallbladder in 2,067, and the papilla of Vater in 785. Those cases were analyzed with regard to patient survival according to the extent of tumor invasion (pT), the extent of lymph node metastasis (pN) and the stage. The five-year survival rate after surgical resection was 33.1% for bile duct cancer, 41.6% for gallbladder cancer, and 52.8% for cancer of the papilla of Vater. For hilar or superior bile duct cancer, the 5-year survival rate was lower with an increase in the pT, pN and f stage, except pT3 vs. pT4, pN1 vs. pN2 and stage III vs. stage IVa. For middle or distal bile duct cancer, the 5-year survival rate was lower with increase in pT, pN and f stage, except pT2 vs. pT3, pN2 vs. pN3, stage II vs. stage III and stage III vs. stage IVa. For gallbladder cancer, the 5-year survival rate was lower with increase in pT, pN and f stage. For cancer of the papilla of Vater, the 5-year survival rate was lower with increase in pT, pN and f stage, except pT1 vs. pT2, pN1 vs. pN2, and stage III vs. stage IVa. In the present study, the outcomes of surgical treatment were better than that of the previous report from Japan and foreign countries. The pT, pN and stage of gallbladder cancer are well defined. However, there were no significant differences in some groups of those of bile duct cancer and cancer of the papilla of Vater.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [1] Biliary tract cancer registry in Japan from 2008 to 2013
    Ishihara, Shin
    Horiguchi, Akihiko
    Miyakawa, Shuichi
    Endo, Itaru
    Miyazaki, Masaru
    Takada, Tadahiro
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2016, 23 (03) : 149 - 157
  • [2] Geographic clustering patterns in mortality from biliary tract cancer in Japan
    Kodama, K
    Nakadaira, H
    Endoh, K
    Yamamoto, M
    JAPANESE JOURNAL OF CANCER RESEARCH, 1998, 89 (01): : 6 - 11
  • [3] Family History of Cancer and Risk of Biliary Tract Cancers: Results from the Biliary Tract Cancers Pooling Project
    Van Dyke, Alison L.
    Langhamer, Margaret S.
    Zhu, Bin
    Pfeiffer, Ruth M.
    Albanes, Demetrius
    Andreotti, Gabriella
    Freeman, Laura E. Beane
    Chan, Andrew T.
    Freedman, Neal D.
    Gapstur, Susan M.
    Giles, Graham G.
    Grodstein, Francine
    Liao, Linda M.
    Luo, Juhua
    Milne, Roger L.
    Monroe, Kristine R.
    Neuhouser, Marian L.
    Poynter, Jenny N.
    Purdue, Mark P.
    Robien, Kim
    Schairer, Catherine
    Sinha, Rashmi
    Weinstein, Stephanie
    Zhang, Xuehong
    Petrick, Jessica L.
    McGlynn, Katherine A.
    Campbell, Peter T.
    Koshiol, Jill
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2018, 27 (03) : 348 - 351
  • [4] Essential updates to the surgical treatment of biliary tract cancer
    Matsukuma, Satoshi
    Tokumitsu, Yukio
    Shindo, Yoshitaro
    Matsui, Hiroto
    Nagano, Hiroaki
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2019, 3 (04): : 378 - 389
  • [5] Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer
    Tsavaris, N
    Kosmas, C
    Gouveris, P
    Gennatas, K
    Polyzos, A
    Mouratidou, D
    Tsipras, H
    Margaris, H
    Papastratis, G
    Tzima, E
    Papadoniou, N
    Karatzas, G
    Papalambros, E
    INVESTIGATIONAL NEW DRUGS, 2004, 22 (02) : 193 - 198
  • [6] New Treatment Options for Advanced Biliary Tract Cancer
    Jonathan D. Mizrahi
    Rachna T. Shroff
    Current Treatment Options in Oncology, 2020, 21
  • [7] Weekly Gemcitabine for the Treatment of Biliary Tract and Gallbladder Cancer
    Nikolas Tsavaris
    Christos Kosmas
    Panagiotis Gouveris
    Kostadinos Gennatas
    Aris Polyzos
    Despina Mouratidou
    Heracles Tsipras
    Helias Margaris
    George Papastratis
    Evanthia Tzima
    Nikitas Papadoniou
    Gavrilos Karatzas
    Efstathios Papalambros
    Investigational New Drugs, 2004, 22 : 193 - 198
  • [8] Adjuvant treatment in biliary tract cancer: To treat or not to treat?
    Cereda, Stefano
    Belli, Carmen
    Reni, Michele
    WORLD JOURNAL OF GASTROENTEROLOGY, 2012, 18 (21) : 2591 - 2596
  • [9] Atezolizumab: an investigational agent for the treatment of biliary tract cancer
    Hack, Stephen P.
    Zhu, Andrew X.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (10) : 1007 - 1015
  • [10] New Treatment Options for Advanced Biliary Tract Cancer
    Mizrahi, Jonathan D.
    Shroff, Rachna T.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2020, 21 (08)